Fulcrum Therapeutics, Inc. (FULC)
- Previous Close
7.28 - Open
7.07 - Bid 7.12 x 100
- Ask 7.17 x 100
- Day's Range
6.85 - 7.18 - 52 Week Range
2.43 - 13.70 - Volume
525,769 - Avg. Volume
639,874 - Market Cap (intraday)
443.155M - Beta (5Y Monthly) 2.28
- PE Ratio (TTM)
-- - EPS (TTM)
-1.59 - Earnings Date May 13, 2024 - May 17, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
13.25
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
www.fulcrumtx.comRecent News: FULC
Performance Overview: FULC
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: FULC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: FULC
Valuation Measures
Market Cap
443.16M
Enterprise Value
217.76M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
155.84
Price/Book (mrq)
1.88
Enterprise Value/Revenue
77.63
Enterprise Value/EBITDA
-2.01
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-28.56%
Return on Equity (ttm)
-44.84%
Revenue (ttm)
2.81M
Net Income Avi to Common (ttm)
-97.33M
Diluted EPS (ttm)
-1.59
Balance Sheet and Cash Flow
Total Cash (mrq)
236.22M
Total Debt/Equity (mrq)
4.60%
Levered Free Cash Flow (ttm)
-56.72M